201 related articles for article (PubMed ID: 15160944)
21. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
22. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Gritti G; Reda G; Maura F; Piciocchi A; Baldini L; Molica S; Neri A; Cortelezzi A
Leuk Lymphoma; 2012 Mar; 53(3):424-9. PubMed ID: 21919823
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
24. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
25. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
26. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
27. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M; Falkner F; Steurer M; Zojer N; Hopfinger G; Haslbauer F; Winder G; Voskova D; Andel J; Lang A; Brychtova Y; Mayer J; Greil R; Gastl G; ; ;
Ann Hematol; 2011 Sep; 90(9):1083-91. PubMed ID: 21350830
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
29. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab in clinical practice: a British Columbia experience.
Hui D; Lam W; Toze C; Delorme M; Noble M; Klimo P; Sutherland J; Gill K; Connors J; Sehn L
Leuk Lymphoma; 2008 Feb; 49(2):218-26. PubMed ID: 18231907
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Lozanski G; Heerema NA; Flinn IW; Smith L; Harbison J; Webb J; Moran M; Lucas M; Lin T; Hackbarth ML; Proffitt JH; Lucas D; Grever MR; Byrd JC
Blood; 2004 May; 103(9):3278-81. PubMed ID: 14726385
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract][Full Text] [Related]
34. The evolving role of alemtuzumab in management of patients with CLL.
Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K
Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912
[TBL] [Abstract][Full Text] [Related]
35. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Faderl S; Thomas DA; O'Brien S; Garcia-Manero G; Kantarjian HM; Giles FJ; Koller C; Ferrajoli A; Verstovsek S; Pro B; Andreeff M; Beran M; Cortes J; Wierda W; Tran N; Keating MJ
Blood; 2003 May; 101(9):3413-5. PubMed ID: 12522009
[TBL] [Abstract][Full Text] [Related]
36. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
37. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
[TBL] [Abstract][Full Text] [Related]
38. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
Ishizawa K; Fukuhara N; Nakaseko C; Chiba S; Ogura M; Okamoto A; Sunaga Y; Tobinai K
Jpn J Clin Oncol; 2017 Jan; 47(1):54-60. PubMed ID: 28122892
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
40. High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Majolino I; Ladetto M; Locasciulli A; Drandi D; Benedetti F; Gallamini A; Chisesi T; De Blasio A; Boccadoro M; Tarella C
Med Oncol; 2006; 23(3):359-68. PubMed ID: 17018893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]